Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2023 16:01 ET | Source: Galecto, Inc.

Galecto Announces Plans to Explore Strategic Alternatives

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today...
August 31, 2023 11:00 ET | Source: Galecto, Inc.

Galecto to Present at Investor Conferences in September

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
August 15, 2023 07:30 ET | Source: Galecto, Inc.

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments...
July 31, 2023 16:05 ET | Source: Galecto, Inc.

Galecto Reports Second Quarter Operating and Financial Results

BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
June 20, 2023 08:58 ET | Source: Galecto, Inc.

Galecto Set to Join Russell Microcap® Index

BOSTON, June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
May 30, 2023 08:00 ET | Source: Galecto, Inc.

Galecto to Present at the Upcoming Jefferies Healthcare Conference

BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
May 23, 2023 08:30 ET | Source: Galecto, Inc.

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
May 17, 2023 16:01 ET | Source: Galecto, Inc.

Galecto to Present Poster at Upcoming ATS 2023 International Conference

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
April 28, 2023 08:00 ET | Source: Galecto, Inc.

Galecto Reports First Quarter Operating and Financial Results

BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...
April 13, 2023 08:30 ET | Source: Galecto, Inc.

Galecto to Present Two Posters at AACR Annual Meeting 2023

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...